alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 226.80 Packaging and labeling. ( a ) Packaging and labeling operations shall be adequately controlled: ( 1 ) To assure that only those Type A medicated article(s) that have met the specifications established in the master-formula records shall be distributed.
( 2 ) To prevent mixups during the packaging and labeling operations.
( 3 ) To assure that correct labeling is employed for each Type A medicated article(s).
( 4 ) To identify Type A medicated article(s) with lot or control numbers that permit determination of the history of the manufacture and control of the batch of Type A medicated article(s).
( b ) Packaging and labeling operations shall provide: ( 1 ) For storage of labeling in a manner to avoid mixups.
( 2 ) For careful checking of labeling for identity and conformity to the labeling specified in the batch-production records.
( 3 ) For adequate control of the quantities of labeling issued for use with the Type A medicated article(s).
( c ) Type A medicated article(s) shall be distributed in suitable containers to insure the safety, identity, strength, and quality of the finished product.
§ 1230.46 Violation. ( a ) If a violation of the Federal Caustic Poison Act is disclosed, the chief of the district shall send to the importer due notice of the nature of the violation and of the time and place where evidence may be presented, showing that the containers should not be refused admission. At the same time similar notice regarding detention of the containers shall be sent to the District Director of Customs, requesting him to refuse delivery thereof or to require their return to customs custody if by any chance the containers were released without the bond referred to in § 1230.41. The time allowed the importer for representations regarding the shipment may be extended at his request for a reasonable period to permit him to secure such evidence.
( b ) If the importer does not reply to the notice of hearing in person or by letter within the time allowed on the notice, a second notice, marked “second and last notice,” shall be sent at once by the chief of the district, advising him that failure to reply will cause definite recommendation to the District Director of Customs that the containers be refused admission and that the containers be exported within 3 months under customs supervision.
###### Editorial Note on Part 184

#### Editorial Note:

Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

#### § 184.1699 Oil of rue.

(a) Oil of rue is the natural substance obtained by steam distillation of the fresh blossoming plants of rue, the perennial herb of several species of *Ruta—Ruta montana* L., *Ruta graveolens* L., *Ruta bracteosa* L., and *Ruta calepensis* L.

(b) Oil of rue meets the specifications of the “Food Chemicals Codex,” 4th ed. (1996), pp. 342-343, which is incorporated by reference in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. Copies are available from the National Academy Press, Box 285, 2101 Constitution Ave. NW., Washington, DC 20055 (Internet address *http://www.nap.edu*), or may be examined at the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500, between 9 a.m. and 4 p.m., Monday through Friday, or at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html.*

(c) The ingredient is used in food under the following conditions:

| Food (as served) | Parts per million | Function |
| --- | --- | --- |
| Baked goods and baking mixes, § 170.3(n)(1), of this chapter | 10 | Flavoring agent and adjuvant, § 170.3(o)(12) of this chapter. |
| Frozen dairy desserts and mixes, § 170.3 (n)(20) of this chapter | 10 | Do. |
| Soft candy, § 170.3(n)(38) of this chapter | 10 | Do. |
| All other food categories | 4 | Do. |

Maximum Usage Levels Permitted

(d) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.

[42 FR 14653, Mar. 15, 1977, as amended at 49 FR 5613, Feb. 14, 1984; 64 FR 1760, Jan. 12, 1999; 81 FR 5596, Feb. 3, 2016; 88 FR 17724, Mar. 24, 2023]
§ 1306.24 Labeling of substances and filling of prescriptions. ( a ) The pharmacist filling a prescription for a controlled substance listed in Schedule III, IV, or V shall affix to the package a label showing the pharmacy name and address, the serial number and date of initial filling, the name of the patient, the name of the practitioner issuing the prescription, and directions for use and cautionary statements, if any, contained in such prescription as required by law.
( b ) If the prescription is filled at a central fill pharmacy, the central fill pharmacy shall affix to the package a label showing the retail pharmacy name and address and a unique identifier, (*i.e.* the central fill pharmacy's DEA registration number) indicating that the prescription was filled at the central fill pharmacy, in addition to the information required under paragraph (a) of this section.
( c ) The requirements of paragraph (a) of this section do not apply when a controlled substance listed in Schedule III, IV, or V is prescribed for administration to an ultimate user who is institutionalized: Provided, That: ( 1 ) Not more than a 34-day supply or 100 dosage units, whichever is less, of the controlled substance listed in Schedule III, IV, or V is dispensed at one time;
( 2 ) The controlled substance listed in Schedule III, IV, or V is not in the possession of the ultimate user prior to administration;
( 3 ) The institution maintains appropriate safeguards and records the proper administration, control, dispensing, and storage of the controlled substance listed in Schedule III, IV, or V; and
( 4 ) The system employed by the pharmacist in filling a prescription is adequate to identify the supplier, the product and the patient, and to set forth the directions for use and cautionary statements, if any, contained in the prescription or required by law.
( d ) All prescriptions for controlled substances listed in Schedules III, IV, and V shall be kept in accordance with § 1304.04(h) of this chapter.
[62 FR 13965, Mar. 24, 1997, as amended at 68 FR 37411, June 24, 2003]
Editorial Note on Part 201
Editorial Note: Nomenclature changes to part 201 appear at 69 FR 13717, Mar. 24, 2004.

§ 201.303 Labeling of drug preparations containing significant proportions of wintergreen oil. ( a ) Because methyl salicylate (wintergreen oil) manifests no toxicity in the minute amounts in which it is used as a flavoring, it is mistakenly regarded by the public as harmless even when taken in substantially larger amounts. Actually, it is quite toxic when taken in quantities of a teaspoonful or more. Wintergreen oil and preparations containing it have caused a number of deaths through accidental misuse by both adults and children. Children are particularly attracted by the odor and are likely to swallow these products when left within reach.
( b ) To safeguard against fatalities from this cause, the Department of Health and Human Services will regard as misbranded under the provisions of the Federal Food, Drug, and Cosmetic Act any drug containing more than 5 percent methyl salicylate (wintergreen oil), the labeling of which fails to warn that use otherwise than as directed therein may be dangerous and that the article should be kept out of reach of children to prevent accidental poisoning.
( c ) This statement of interpretation in no way exempts methyl salicylate (wintergreen oil) or its preparations from complying in all other respects with the requirements of the Federal Food, Drug, and Cosmetic Act.
<PAGE>
                                   EXHIBIT 23
                                   ----------

                       CONSENT OF INDEPENDENT ACCOUNTANTS
                       ----------------------------------


We hereby consent to the incorporation by reference in the Registration
Statements on Form S-8 (No. 2-74896, No. 33-38737 and No. 33-73044), in the
Registration Statement on Form S-3 (No. 33-71030) and in the Registration
Statement on Form S-4 (No. 33-65229) of Bell Industries, Inc. of our report
dated February 14, 2002 relating to the financial statements and financial
statement schedule, which appears in this Form 10-K.



PricewaterhouseCoopers LLP

Los Angeles, California
March 28, 2002
§ 1401.11 Fees to be charged—general. ONDCP will assess a fee to process FOIA requests in accordance with the provisions of this section and Uniform Freedom of Information Fee Schedule and Guidelines published by the Office of Management and Budget (“OMB Guidelines”). ONDCP shall ensure that searches, review and duplication are conducted in the most efficient and the least expensive manner. ONDCP will ordinarily collect all applicable fees before sending copies of records to a requester. ONDCP will charge the following fees unless a waiver or reduction of fees is granted under § 1401.15, or the total fee to be charged is less than $25.00. ONDCP will notify you if we estimate that charges will exceed $25.00 including a breakdown of the fees for search, review or duplication and whether applicable entitlements to duplication and search at no charge have been provided. ONDCP will not process your request until you either commit in writing to pay the actual or estimated total fee, or designate some amount of fees you are willing to pay. ( a ) *Search for records.* ONDCP will charge $77.00 per hour, which is a blended hourly rate for all personnel that respond to FOIA requests plus 16 percent of that rate to cover benefits.
( b ) *Review of records.* ONDCP will charge $77.00 per hour, which is a blended hourly rate for all personnel that responded to FOIA requests plus 16 percent of that rate to cover benefits. Records or portions of records withheld under an exemption subsequently determined not to apply may be reviewed to determine the applicability of exemptions not considered. The cost for a subsequent review is assessable.
( c ) *Duplication of records.* We will charge duplication fees to all requesters. We will honor your preference for receiving a record in a particular format if we can readily reproduce it in the form or format requested. If we provide photocopies, we will make one copy per request at the cost of $.10 per page. For copies of records produced on tapes, disks or other media, we will charge the direct costs of producing the copy, including operator time. Where we must scan paper documents in order to comply with your preference to receive the records in an electronic format, we will charge you the direct costs associated with scanning those materials. For other forms of duplication, we will charge the direct costs. We will provide the first 100 pages of duplication (or the cost equivalent for other media) without charge except for requesters seeking records for a commercial use.
( d ) *Other charges.* ONDCP will recover the costs of providing other services such as certifying records or sending records by special methods.
#### STATE OF NEW JERSEY, DEFENDANT IN ERROR, v. EDWIN W. DORCH, PLAINTIFF IN ERROR.

Submitted February 17, 1939

Decided April 21, 1939.

For the defendant in error, *David T. Wilentz,*attorney-general, and *Alexander F. Ormsby,*assistant attorney-general.

For the plaintiff in error, *Thomas Brunetto.*

Per Curiam.

The judgment tinder review herein should be affirmed, for the reasons expressed in the opinion delivered by Mr. Justice Perskie in the Supreme Court.

*For affirmance*— The Chancellor, Chief Justice, Parker, Case, Bodine, Donges, Porter, Hetfield, Dear, Wells, WolfsKeil, Rafferty, Hague, JJ. 13.

*For reversal*— None.
773 P.2d 356

#### In the Matter of Inquiry Concerning a Judge, No. 690: Honorable Ignacio N. GARCIA, Magistrate.

No. 18385.

Supreme Court of New Mexico.

May 15, 1989.

ORDER

PER CURIAM.

This matter coming on for consideration by the Court upon the Report of Findings of fact, Conclusions of Law and Recommendation of the Judicial Standards Commission based upon a Stipulation and Agreement between Respondent Ignacio N. Garcia, being approved by his attorney, Michael S. Sanchez, and Samuel W. Jones for the Commission, and the Court having considered the matter and being sufficiently advised;

NOW, THEREFORE, IT IS ORDERED that the recommendations of the Judicial Standards Commission are hereby adopted by the Court, as follows:

(1) Ignacio N. Garcia is hereby suspended from his position as Magistrate Judge, Division I, Socorro, New Mexico, for a period of two months, of which one month will be without pay, said suspension to begin May 15, 1989.

(2) Ignacio N. Garcia will, during the period of his absence, seek out and participate in a training course designed for magistrate judges and will make the necessary arrangements to work with one or more fellow magistrates on a daily basis for a minimum of thirty (30) days. He will obtain prior approval from the Judicial Standards Commission as to his selection of the training course and the fellow magistrates and will furnish evidence of satisfactory compliance to the Administrative Office of the Courts. He will bear the cost of the training.

(3) Upon returning to the bench following his period of suspension, Ignacio N. Garcia will be on probation for one year during which time he will be subject to periodic review by the Administrative Office of the Courts.

(4) The Judicial Standards Commission will retain jurisdiction of these proceedings to ensure compliance.

(5) Ignacio N. Garcia will pay the costs incurred by the Judicial Standards Commission in this matter in the sum of $507.78.

(6) That as provided in the Stipulation and Agreement, Ignacio N. Garcia will help to cause the Socorro County Court to be moved to acceptable quarters.

IT IS SO ORDERED.
###### Editorial Note on Part 17

#### Editorial Note:

Nomenclature changes to part 17 appear at 68 FR 24879, May 9, 2003, and at 88 FR 45065, July 14, 2023.

#### § 17.43 Posthearing briefs.

Any party may file a posthearing brief. The presiding officer shall fix the time for filing such briefs (which shall be filed simultaneously), which shall not exceed 60 days from the date the parties received the transcript of the hearing or, if applicable, the stipulated record. Such briefs may be accompanied by proposed findings of fact and conclusions of law. The presiding officer may permit the parties to file responsive briefs. No brief may exceed 30 pages (exclusive of proposed findings and conclusions) unless the presiding officer has previously found that the issues in the proceeding are so complex, or the administrative record is so voluminous, as to justify longer briefs, in which case the presiding officer may set a longer page limit. Proposed findings of fact and conclusions of law shall not exceed 30 pages unless the presiding officer has previously found that the issues in the proceeding are so complex, or the administrative record is so voluminous, as to justify longer proposed findings and conclusions, in which case the presiding officer may set a longer page limit.
[No. 39158-5-I.

Division One.

December 8, 1997.]

#### The State of Washington, *Respondent,*v. Lee Edward Shadrick, *Appellant.*

Appeal from a judgment of the Superior Court for King County, No. 96-1-02960-9, Richard A. Jones, J., entered July 29, 1996. *Affirmed*by unpublished per curiam opinion.
I 

118TH CONGRESS 

2D SESSION H. R. 7148 

To amend title XVIII of the Social Security Act to provide for eligibility 

for coverage of home health services under the Medicare Program on 

the basis of a need for occupational therapy. 

IN THE HOUSE OF REPRESENTATIVES 

JANUARY 30, 2024 

Mr. SMUCKER (for himself, Mr. DOGGETT, Mr. TONKO, and Mr. JOYCE of 

Pennsylvania) introduced the following bill; which was referred to the 

Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the 

Speaker, in each case for consideration of such provisions as fall within 

the jurisdiction of the committee concerned 

A BILL 

To amend title XVIII of the Social Security Act to provide 

for eligibility for coverage of home health services under 

the Medicare Program on the basis of a need for occupational therapy. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Medicare Home Health 

5 Accessibility Act’’. 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 7148 IH

1 SEC. 2. ELIGIBILITY FOR HOME HEALTH SERVICES ON THE 

2 BASIS OF A NEED FOR OCCUPATIONAL THER3 APY. 

4 (a) IN GENERAL.—Sections 1814(a)(2)(C) and 

5 1835(a)(2)(A) of the Social Security Act (42 U.S.C. 

6 1395f(a)(2)(C); 1395n(a)(2)(A)) are each amended by 

7 striking ‘‘or speech therapy’’ and all that follows through 

8 ‘‘need occupational therapy’’ and inserting ‘‘, occupa9 tional, or speech therapy’’. 

10 (b) EFFECTIVE DATE.—The amendments made by 

11 subsection (a) shall apply to home health services provided 

12 on or after January 1, 2025. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS
Exhibit 32.01

SECTION 906 CERTIFICATIONS

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of Amerityre Corporation (the "Company") on Form 10-
KSB for the fiscal year ended June 30, 2004, as filed with the Securities and
Exchange Commission on the date hereof (the "Report"), I, Richard A. Steinke,
Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
that, to the best of my knowledge and belief:

 (1) the Report fully complies with the requirements of Section 13(a) or 15(d)
of the Securities Exchange Act of 1934; and

 (2) the information contained in the Report fairly presents, in all material
respects, the financial condition and result of operations of the Company.


/S/ Richard A. Steinke
Richard A. Steinke
Chief Executive Officer

September 26, 2004

A signed original of this written statement required by Section 906, or other
document authenticating, acknowledging, or otherwise adopting the signature
that appears in typed form within the electronic version of this written
statement has been provided to the Company and will be retained by the Company
and furnished to the Securities and Exchange Commission or its staff upon
request.
Editorial Note on Part 9
Editorial Note: Nomenclature changes to part 9 appear at 82 FR 52825, Nov. 15, 2017.

§ 9.201 Production or disclosure prohibited unless approved by appropriate NRC official. ( a ) No employee of the NRC shall, in response to a demand of a court or other judicial or quasi-judicial authority, produce any material contained in the files of the NRC or disclose, through testimony or other means, any information relating to material contained in the files of the NRC, or disclose any information or produce any material acquired as part of the performance of that employee's official duties or official status without prior approval of the appropriate NRC official. When the demand is for material contained in the files of the Office of the Inspector General or for information acquired by an employee of that Office, the Inspector General is the appropriate NRC official. In all other cases, the General Counsel is the appropriate NRC official.
( b ) Any NRC response to a demand of a court or other judicial or quasi-judicial authority that requires an employee of the NRC to expend more than 50 hours of official time shall be subject to hourly fees in accordance with 10 CFR 170.12(d).
[81 FR 41185, June 24, 2016]
#### § 20.84 Disclosure to consultants, advisory committees, State and local government officials commissioned pursuant to 21 U.S.C. 372(a), and other special government employees.

Data and information otherwise exempt from public disclosure may be disclosed to Food and Drug Administration consultants, advisory committees, State and local government officials commissioned pursuant to 21 U.S.C. 372(a), and other special government employees for use only in their work with the Food and Drug Administration. Such persons are thereafter subject to the same restrictions with respect to the disclosure of such data and information as any other Food and Drug Administration employee.
“Articles of Incorporation”

2015

BarryAir LLC

1.) BarryAir LLC is incorporated in Louisiana.

2.) BarryAir LLC is incorporated for an unlimited duration.

3.) BarryAir LLC is incorporated to participate in all Lawful Business.

4.) BarryAir LLC mailing adress is 210 Rue Chavaniac, Lafayette, Louisiana 70508-7314

5.) BarryAir LLC Owner/Director, is Barry L. Tanner Sr.

6.) Corporation By Laws: are to conduct and operate business observing all State and Federal Law as closely 

as possible, with due diligence.

7.) Dissolution: The officers of BarryAir LLC reserver the right to dissolve BarryAir LLC for any 

circumstance deemed worthy.

8.) Indemnification of Officers and Directors: BarryAir shall be held harmless from all claims, losses, 

expenses, and fees, including attorney fees, costs, and judgments that may be asserted against BarryAir LLC, 

BarryAir LLC employees, and BarryAir LLC agents.

BarryAir LLC: Agents include, 1.) Barry Tanner Jr. 2.) Ulrike Hoffmann Tanner

10.) Incorporator Information:

BarryAir LLC was formed by Barry Tanner Sr. in order to conduct business in a safe and lawful manner.

Barry Tanner Sr.

201 Rue Chavaniac

Lafayette, Louisiana

70508

337-315-0829

barryair@cox.net

videodronedude@yahoo.com
<PAGE>

                                                                 EXHIBIT 10.18.3


                             THIRD AMENDMENT TO THE

                                 PROMISSORY NOTE

This THIRD AMENDMENT ("Amendment") dated as of January 1, 2002, by WFS FINANCIAL
INC, a California corporation ("WFS"), and WESTERN FINANCIAL BANK, formerly
known as Western Financial Bank, F.S.B. ("WFB") amends the PROMISSORY NOTE
("Note") executed by WFS in favor of WFB on August 1, 1997. Capitalized terms
not defined herein shall have the same meaning as defined in the Note.

The Note is hereby amended to:

1.      Increase the principal amount from $67,500,000 to $150,000,000;

2.      Decrease the rate of interest on the Note from 9.420% to 8.875%; and

3.      Amend the scheduled payment of Principal such that Principal shall now
        be all due and payable on or before August 1, 2007 (the "Maturity"),
        except that, notwithstanding anything to the contrary, WFB shall have
        the exclusive option to require WFS to pay all or part of the Principal
        at any time from the date hereof to the Maturity.

Except as specifically amended herein, all terms and conditions of the Note
shall remain in full force and effect.

Wherefore, WFS and WFB have caused this Amendment to be executed and delivered
by its duly authorized signatory as of the date first set forth above.

WFS FINANCIAL INC


By:
     ---------------------------
     Thomas A. Wolfe

Its: President

WESTERN FINANCIAL BANK


By:
     ---------------------------
     J. Keith Palmer

Its: SVP & Treasurer